Axillary metastasis as the first manifestation of male breast cancer: a case report

Gu, Guo-Li; Wang, Shilin; Wei, Xueming; Ren, Li; Zou, Fu-Xian

doi:10.1186/1757-1626-1-285

Cited by 12 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Rarely, patients may present with axillary lymphadenopathy alone or with Paget disease of the breast. 3,5 Nipple involvement usually occurs earlier in the disease when compared with FBC; typical changes are ulceration, retraction, or discharge. 4 As in FBC, triple assessment (clinical examination followed by imaging and biopsy) is the criterion standard when diagnosing MBC.…”

Section: The Diagnostic Pathwaymentioning

confidence: 99%

New Approaches in the Management of Male Breast Cancer

Patten

Sharifi

Fazel

2013

Clinical Breast Cancer

View full text Add to dashboard Cite

Section: The Diagnostic Pathwaymentioning

confidence: 99%

New Approaches in the Management of Male Breast Cancer

Patten

Sharifi

Fazel

2013

Clinical Breast Cancer

View full text Add to dashboard Cite

“…25 Axillary node metastases appear to be more common in males as opposed to females, and cases of occult breast cancer have been reported in the literature. 26,27 …”

Section: Diagnosismentioning

confidence: 99%

Male breast cancer: An update in diagnosis, treatment and molecular profiling

et al. 2010

View full text Add to dashboard Cite

Significant advances have been made in the diagnosis and treatment of female breast cancer, resulting in a decline in incidence and a global improvement in clinical outcome. The statistics for male breast cancer (MBC) stand in sharp contrast – over the past several decades, there has been a steady rise in the incidence of this disease, and clinical outcome has improved at a much slower pace. In the current review, the clinicopathologic features of MBC are described in detail. An emphasis is placed on molecular profiling of MBC, which may identify candidate biomarkers and putative targets for pharmacologic intervention. The current role of cytotoxic chemotherapy and endocrine therapy (including tamoxifen, aromatase inhibitors and GnRH analogues) is defined in the context of currently available studies. Furthermore, the potential role of targeted agents, including HER2-directed therapies, PARP inhibitors, and angiogenesis inhibitors, is delineated.

show abstract

“…The occurrence of occult breast cancer in a male is even rarer, although some cases have been reported [3, 4]. Here, we report a male having epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer.…”

Section: Introductionmentioning

confidence: 80%

“…The skin lesion was diagnosed as skin metastases from possible occult breast cancer. Occult breast cancer commonly presents lymph node metastasis of the axilla, supraclavicular fossa and infraclavicular fossa as first manifestation [ 4 , 5 ]. One differential diagnosis is primary carcinoma of an accessory mammary gland.…”

Section: Discussionmentioning

confidence: 99%

“…Breast cancer in a male is very rare, comprising less than 1% of all breast cancers and less than 1% of all cancers in men [ 1 , 2 ]. The occurrence of occult breast cancer in a male is even rarer, although some cases have been reported [ 3 , 4 ]. Here, we report a male having epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transient Effectiveness of an Oral 5-Fluorouracil Derivative, S-1, for Epirubicin, Cyclophosphamide and Paclitaxel Refractory Skin Metastases from Possible Occult Breast Cancer in a Male

Hirao

Oiso

Tsurutani³

et al. 2011

Case Rep Dermatol

View full text Add to dashboard Cite

Recent chemotherapies for skin metastases from breast cancer have shown to be effective for regression, disappearance, and favorable quality of life. We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer. The male patient was initially diagnosed as having lymph node metastases in the left axilla as possible occult breast cancer. The skin metastases developed after chemotherapy with a combination of epirubicin and cyclophosphamide, subsequent chemotherapy with paclitaxel, and radiotherapy. Chemotherapy with paclitaxel was resumed for skin metastases, but it was not effective. Alternative chemotherapy with the oral agent S-1 was administered. The skin metastases completely disappeared after the second course, but recurred at the end of the third course. This case suggests that S-1 may be a candidate for chemotherapy for skin metastases from occult breast cancer in males.

show abstract

Axillary metastasis as the first manifestation of male breast cancer: a case report

Abstract: Background: Breast cancer is very rare in men, and the occurrence of occult breast cancer which present axillary metastasis as the first manifestation is even rarer in men.

Cited by 12 publications

References 9 publications

New Approaches in the Management of Male Breast Cancer

New Approaches in the Management of Male Breast Cancer

Male breast cancer: An update in diagnosis, treatment and molecular profiling

Transient Effectiveness of an Oral 5-Fluorouracil Derivative, S-1, for Epirubicin, Cyclophosphamide and Paclitaxel Refractory Skin Metastases from Possible Occult Breast Cancer in a Male

Contact Info

Product

Resources

About